MDT closed its fiscal fourth quarter with analysts cutting targets on earnings day itself — a clear signal that the Q4 print failed to close the gap between Street expectations and what the company actually delivered.
The most telling move of the week came from the analysts. Mizuho and Needham both trimmed their price targets on June 3 — the day of the earnings release — slashing from $120 to $100 and $101 respectively, while maintaining their positive ratings. That pattern echoes the broader analyst behaviour since April, when virtually every firm updated its view by marking numbers down rather than leaning in. The consensus target has now slipped to $105.76, down from $106.56 cited in last week's earnings preview, and the gap to the current price of $73.75 remains painfully wide at roughly 43%. Bulls still point to the portfolio breadth, new product launches following the diabetes divestment, and the Scientia Vascular acquisition as longer-term drivers. Bears argue that F3Q26's 6.0% organic growth already came in below expectations, and Q4 has done nothing to reset that concern. The most recent ORTEX stock score note flagged quality as the standout pillar — an F-score of 8 and solid FCF margins — but the momentum picture has deteriorated as the stock shed 5% on the week and nearly 8% over the past month.
The price reaction tells its own story. MDT fell to $73.75 — its lowest level in recent months — and the move is sector-wide in character rather than idiosyncratic. Close peers also struggled: SYK fell 6.3% on the week, GMED dropped 8%, and MMSI gave back 5.6%. COO held up better, off just 4.1%. The selling pressure is therefore broad, though MDT's absolute level — already trading at a discount to large-cap medtech — means its valuation compression is compounding rather than merely tracking the sector. Price-to-book has dropped 12% over the past 30 days to 1.82x, and the PE of 11.8x is similarly contracting, having fallen roughly 0.8 turns over the same period.
Options positioning has drifted more cautious than usual, though not dramatically so. The put/call ratio moved to 0.57, about 1.4 standard deviations above its 20-day average of 0.52 — a mild defensive lean rather than a panic hedge. The 52-week range for the PCR runs from 0.39 to 1.01, so the current reading is well within normal territory. Short interest adds little to the bear case here: at 1.2% of the free float, it is low by any measure, and while it has crept up about 3% over the past week and month, the borrow market remains completely unencumbered. Availability is effectively unlimited — over 1.27 billion shares remain available to lend against roughly 15 million short — and cost to borrow is negligible at 0.32%. Short sellers are not the story; this is a fundamental re-rating.
Insider activity from late May adds a small footnote. A cluster of equity awards landed on May 26 — CEO Geoff Martha received 94,963 shares and several EVPs received smaller tranches — but these were non-cash awards at zero price, carrying minimal trade significance. The only open-market transactions in the window were trivial sales by two directors in late April, each under $17,000. Net insider activity over the past 90 days is marginally positive at roughly $452,000, but the signal is noise-level against a company of this size.
What to watch next is whether the post-earnings analyst revision cycle stabilises or accelerates: several firms that last updated in mid-April — including UBS at $90 and Truist at $95 — have not yet reacted to the Q4 print, and their next moves will determine whether the consensus target begins to compress meaningfully toward where the stock is actually trading.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
